Tamoxifen 10 mg Tablets
10 mg · 100 tablets · Tamoxifen is a selective estrogen-receptor modulator (SERM) used in HPG-axis stimulation studies, ER-positive tumor research, gynecomastia models, and endocrine-feedback investigations due to its strong ER-α/β antagonism and long half-life.
€ 39.00
Beschreibung
Tamoxifen 10 mg Tablets — Swiss Remedies
Brand: Swiss Remedies
Category: SERM Research Compound
Content: 100 tablets × 10 mg (1,000 mg total)
Price: €29
Manufactured in: Switzerland
🧪 Product Overview
Tamoxifen 10 mg is a selective estrogen-receptor modulator (SERM) widely used in
endocrinology, oncology, and reproductive-physiology research. By antagonizing ER-α/β
receptors, tamoxifen reduces estrogenic negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis,
thereby increasing luteinising hormone (LH), follicle-stimulating hormone (FSH), and endogenous testosterone
levels in male research models.
In female models, tamoxifen remains the reference anti-estrogen for ER-positive tumor studies
and is foundational in breast-cancer research methodologies. Its long half-life (parent: 4–11 days;
active metabolite endoxifen: 50–70 h) ensures stable receptor occupancy and consistent endocrine modulation.
✅ Key Research Highlights
HPG-axis stimulation:
Studies show that 10–20 mg/day for 3 months can double serum testosterone in hypogonadal men (PMC).
Gynecomastia regression models:
Clinical literature demonstrates breast-tissue reduction with 10–20 mg/day during anabolic-steroid cycles.
Anti-estrogen gold standard:
Primary SERM model for ER-positive tumor studies and comparative endocrine research.
Pharmacokinetics:
~100% oral bioavailability; parent half-life 4–11 days; active metabolite half-life 50–70 h.
Research logistics:
Film-coated tablets stable ≤25 °C with 36-month shelf-life, simplifying storage compared to parenteral SERMs.
🧬 Suggested Laboratory Applications
- ER-α/β modulation studies
- HPG-axis regulation and testosterone-restoration experiments
- Gynecomastia and anti-estrogenic pathway research
- ER-positive tumor and endocrine oncology models
- Comparative SERM pharmacology and metabolite profiling
📊 Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Tamoxifen (base); supplied as Tamoxifen Citrate |
| Chemical Formula | C26H29NO (base) |
| Synonyms | Nolvadex; TMX; 4-(1-dimethylaminoethoxy)-diphenyl-1-ethenyl-phenol |
| Molecular Weight | 371.5 g/mol (base); 563.6 g/mol (citrate) |
| CAS Numbers | 10540-29-1 (base); 54965-24-1 (citrate) |
| PubChem-Documented Benefits |
• Blocks ER feedback → ↑ LH/FSH → ↑ testosterone • Standard SERM for ER-positive tumor research • Gynecomastia regression documentation |
| Documented Risks / Side-Effects |
Hot-flushes; transient visual changes; thrombo-embolism risk; cataract associations; lipid shifts; reduced bone-mineral density |
| Total Active Compound | 1,000 mg tamoxifen base (10 mg × 100 tablets) |
| Shelf-Life | 36 months (sealed; ≤25 °C; protect from light) |
❄️ PubChem-Supported Research Insights
- Strong ER-blockade increases gonadotropin secretion
- Primary comparator in SERM and anti-estrogen studies
- Supports ER-positive cancer research and endocrine therapy modeling
- Long half-life enables extended receptor modulation
- Active metabolites contribute to prolonged efficacy and pharmacodynamics
⚠️ Documented Research Side Effects
- Hot-flushes and vasomotor symptoms
- Visual blurring and reported cataract risk
- Thrombo-embolic events and lipid-profile shifts
- Reduced bone-mineral density during prolonged exposure
- Fatigue and mood changes reported in some literature
🧯 Handling & Compliance
For Research Use Only – not for dietary, therapeutic, or veterinary use.
Tamoxifen is prohibited under WADA S4 (Hormone Modulators); any exposure may trigger positive doping results.
Purchase confirms qualified-researcher status and acceptance of all handling liability.
Store sealed, protected from heat and light, and follow institutional chemical-safety protocols.
There are no reviews yet.
